Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Chemotherapy, Adjuvant
/ methods
Colonic Neoplasms
/ drug therapy
Disease-Free Survival
Drug Combinations
Feasibility Studies
Female
Humans
Male
Middle Aged
Oxaliplatin
/ administration & dosage
Oxonic Acid
/ administration & dosage
Survival Rate
Tegafur
/ administration & dosage
Adjuvant chemotherapy
C-SOX
Multicenter single-arm open-label prospective phase II clinical trial
Stage III colon cancer
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
13
08
2019
accepted:
24
02
2020
pubmed:
20
3
2020
medline:
11
8
2020
entrez:
20
3
2020
Statut:
ppublish
Résumé
Adjuvant chemotherapy is an accepted treatment to improve survival rates in patients with stage III colon cancer, and regimens including oxaliplatin have been shown to be superior to those containing 5-FU alone. The purpose of this study was to examine the efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) as adjuvant chemotherapy for patients with stage III colon cancer following curative resection. Patients with colon cancer who underwent curative resection were enrolled and received oral S-1 40-60 mg twice daily on days 1-14 every 3 weeks plus intravenous oxaliplatin 130 mg/m Between February 2014 and December 2014, 89 patients were enrolled. One patient was excluded from the analysis because of ineligibility, and the remaining 88 patients were included. The rate of protocol treatment completion was 72.3%. The relative dose intensity of S-1 and oxaliplatin was 72% and 76.3%, respectively. Hematological severe adverse events (Grade 3/4) were neutropenia (21.3%) and thrombocytopenia (15.7%). The most frequent symptom was diarrhea (Grade 3/4: 5.6%). The incidence of grade 2 neuropathy has decreased from 8.1 to 2.7% after 3 years of the therapy. Three-year disease-free survival rate was 73.9% (95% CI 63.8-81.9), and 3-year overall survival rate was 94.3% (95% CI 86.8-97.6) CONCLUSIONS: C-SOX is a safe and feasible adjuvant chemotherapy regimen in patients with stage III colon cancer undergoing curative resection.
Sections du résumé
BACKGROUND
BACKGROUND
Adjuvant chemotherapy is an accepted treatment to improve survival rates in patients with stage III colon cancer, and regimens including oxaliplatin have been shown to be superior to those containing 5-FU alone. The purpose of this study was to examine the efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) as adjuvant chemotherapy for patients with stage III colon cancer following curative resection.
METHODS
METHODS
Patients with colon cancer who underwent curative resection were enrolled and received oral S-1 40-60 mg twice daily on days 1-14 every 3 weeks plus intravenous oxaliplatin 130 mg/m
RESULTS
RESULTS
Between February 2014 and December 2014, 89 patients were enrolled. One patient was excluded from the analysis because of ineligibility, and the remaining 88 patients were included. The rate of protocol treatment completion was 72.3%. The relative dose intensity of S-1 and oxaliplatin was 72% and 76.3%, respectively. Hematological severe adverse events (Grade 3/4) were neutropenia (21.3%) and thrombocytopenia (15.7%). The most frequent symptom was diarrhea (Grade 3/4: 5.6%). The incidence of grade 2 neuropathy has decreased from 8.1 to 2.7% after 3 years of the therapy. Three-year disease-free survival rate was 73.9% (95% CI 63.8-81.9), and 3-year overall survival rate was 94.3% (95% CI 86.8-97.6) CONCLUSIONS: C-SOX is a safe and feasible adjuvant chemotherapy regimen in patients with stage III colon cancer undergoing curative resection.
Identifiants
pubmed: 32189156
doi: 10.1007/s10147-020-01646-5
pii: 10.1007/s10147-020-01646-5
doi:
Substances chimiques
Drug Combinations
0
Oxaliplatin
04ZR38536J
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115-1122Références
Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. https://doi.org/10.1056/NEJMoa032709
doi: 10.1056/NEJMoa032709
pubmed: 15175436
Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. https://doi.org/10.1200/JCO.2008.20.6771
doi: 10.1200/JCO.2008.20.6771
pubmed: 19451431
Andre T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33(35):4176–4187. https://doi.org/10.1200/JCO.2015.63.4238
doi: 10.1200/JCO.2015.63.4238
pubmed: 26527776
Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465–1471. https://doi.org/10.1200/JCO.2010.33.6297
doi: 10.1200/JCO.2010.33.6297
pubmed: 21383294
Kuebler JP, Colangelo L, O'Connell MJ et al (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 110(9):1945–1950. https://doi.org/10.1002/cncr.23013
doi: 10.1002/cncr.23013
pubmed: 17853393
Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378(13):1177–1188. https://doi.org/10.1056/NEJMoa1713709
doi: 10.1056/NEJMoa1713709
pubmed: 29590544
pmcid: 6426127
Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557
doi: 10.1097/00001813-199607000-00010
pubmed: 8862723
Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14(13):1278–1286. https://doi.org/10.1016/S1470-2045(13)70490-X
doi: 10.1016/S1470-2045(13)70490-X
pubmed: 24225157
Hong YS, Park YS, Lim HY et al (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13(11):1125–1132. https://doi.org/10.1016/S1470-2045(12)70363-7
doi: 10.1016/S1470-2045(12)70363-7
pubmed: 23062232
Hamaguchi T, Shimada Y, Mizusawa J et al (2018) Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3(1):47–56. https://doi.org/10.1016/S2468-1253(17)30297-2
doi: 10.1016/S2468-1253(17)30297-2
pubmed: 29079411
Andre T, Iveson T, Labianca R et al (2013) The IDEA (International duration evaluation of adjuvant chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorect Cancer Rep 9:261–269. https://doi.org/10.1007/s11888-013-0181-6
doi: 10.1007/s11888-013-0181-6
Yoshino T, Yamanaka T, Oki E et al (2019) Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2572
doi: 10.1001/jamaoncol.2019.2572
pubmed: 31513248
pmcid: 6743062
Kotaka M, Yamanaka T, Yoshino T et al (2018) Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open 3(3):e000354. https://doi.org/10.1136/esmoopen-2018-000354
doi: 10.1136/esmoopen-2018-000354
pubmed: 29713499
pmcid: 5922566
Sobrero A, Grothey A, Iveson T et al (2018) The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? Ann Oncol 29(5):1099–1107. https://doi.org/10.1093/annonc/mdy064
doi: 10.1093/annonc/mdy064
pubmed: 29438451
pmcid: 6864492